Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Clover Health Investments, Corp. (CLOV) SEC Filings & Earnings Calls

EquiReason read 23 Clover Health Investments, Corp. SEC filings in the last 12 months. Latest: 8-K on 2026-10-09 — CMS awarded Clover's PPO MA plans 5 Stars and HMO plan 4.5 Stars for 2027, enabling year-round enrollment and higher payments; core HEDIS score remains 4.82/5, ranking #1 among non.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CLOVClover Health Investments, Corp.Follow CLOV — free
Healthcare Plans · Healthcare
—
Price chart with a free account
Market cap
2.4B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
4 Nov, in 11 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

9 Oct 20268-K · 7.01CMS awarded Clover's PPO MA plans 5 Stars and HMO plan 4.5 Stars for 2027, enabling year-round enrollment and higher payments; core HEDIS score remains 4.82/5, ranking #1 among non-SNP PPO plans.open

Figures in the filing · each found in the filing text

Medicare Advantage membership · H1-2026157,000+48% y/y
HEDIS score · 2027$4.82

Risks flagged

Ongoing litigation with CMS over Star rating calculation methodology; if appeal reverses, PPO rating could drop to 4.5 Stars

“CMS calculated rating removing 20 measures per court decision; with those measures included, PPO would have received 4.5 Stars; case is on appeal”
Read the original on SEC EDGAR ↗
24 Sep 20268-K · 5.02Clover Health Investments appointed Senator Robert G. Torricelli and Dr. Brian J. Miller to its Board of Directors, filling two vacancies. No departure of existing officers; routine board expansion.SEC ↗
20 Aug 20268-K · 7.01Insurance Gross Profit PMPM Year 3 vs Year 1 $155.00; MCR Improvement CA-Managed vs Non-CA Year 3 18; CKD Diagnosis Earlier with CA 18open

Figures in the filing · each found in the filing text

Insurance Gross Profit PMPM Year 3 vs Year 1$155.00
MCR Improvement CA-Managed vs Non-CA Year 318.0%
CKD Diagnosis Earlier with CA$18.00
Kidney Function Decline Slowing with CA72.0%

Risks flagged

Operating expense ratio currently higher than peers due to deliberate investments; expected to improve with scale.

“Operating expense ratio higher than peers; company views this as temporary and expects operating leverage over time.”
Read the original on SEC EDGAR ↗
7 Aug 202610-QClover Health reported strong Q2 2026 results with revenue up 56% YoY, net income of $28M vs loss in prior year, and improved margins.open

Figures in the filing · each found in the filing text

Total revenues · Consolidated · Q2-2026$743M+56% y/y
Total revenues · Consolidated · H1-2026$1.49B+59% y/y
Net income (loss) · Consolidated · Q2-2026$28M
Net income (loss) · Consolidated · H1-2026$55M
Adjusted EBITDA · Consolidated · Q2-2026$41M+139% y/y
Adjusted EBITDA · Consolidated · H1-2026$81M+89% y/y
Average Medicare Advantage membership · Insurance · Q2-2026156,840+49% y/y
Insurance Benefits Expense Ratio · Insurance · Q2-202687.6%
Cash, cash equivalents, and investments · Consolidated · 2026-06-30$443M

Risks flagged

CMS Star Ratings litigation risk

“On July 21, 2026, CMS filed its Notice of Appeal of the district court's decision in the Stars Litigation with the United States Court of Appeals for the Eleventh Circuit.” · word for word

Interest rate sensitivity on investment income

“Other income decreased by $2.4 million, or 31%, to $5.4 million for the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The decrease was primarily driven by ... lower investment income resulting from a lower interest rate environment, to which our returns are closely correlated given the short-duration nature of our invest” · word for word
Read the original on SEC EDGAR ↗
5 Aug 20268-K · 2.02Total revenues $743M (+56% y/y); Consolidated Gross Profit $153M (+54% y/y); Net income (loss) $28M; Guidance: Revenue raised to $2.92B-$3.00B; Gross Profit to $525M-$555M; Adjusted EBITDA to $70M-$85M; GAAP Net Income to $20M-$35Mearningsopen

Figures in the filing · each found in the filing text

Total revenues · Q2-2026$743M+56% y/y
Consolidated Gross Profit · Q2-2026$153M+54% y/y
Net income (loss) · Q2-2026$28M
Adjusted EBITDA · Q2-2026$41M+139% y/y
Average Medicare Advantage membership · Insurance · Q2-2026156,840+49% y/y
Insurance BER · Insurance · Q2-202687.6%
Total cash, cash equivalents, and investments · Q2-2026$443M+14% y/y

Guidance

Revenue raised to $2.92B-$3.00B; Gross Profit to $525M-$555M; Adjusted EBITDA to $70M-$85M; GAAP Net Income to $20M-$35M

Full-year guidance raised across all metrics, reflecting strong Q2 performance and confidence in 2027.

Risks flagged

Elevated cost trends and macro headwinds could impact future performance; reliance on Medicare Advantage star ratings.

“Company maintains cautious view for remainder of year in light of continued elevated cost trends and potential for macro headwinds.”
Read the original on SEC EDGAR ↗
17 Jul 20268-K · 8.01Clover Health detects anomalous login activity; social engineering attack on three employee accounts; PHI/PII potentially accessed; no material impact expected.open

Risks flagged

Cybersecurity incident: social engineering attack on three employee accounts with access to member PII/PHI.

“a threat actor gained access to three non-managerial health plan employee accounts through social engineering... had access to certain personally identifiable information and protected health information” · word for word

Potential regulatory investigations and litigation from the incident.

“the outcome of any regulatory investigations or litigation” · word for word
Read the original on SEC EDGAR ↗
18 Jun 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement)SEC ↗
16 Jun 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)SEC ↗
10 Jun 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement)SEC ↗
18 May 20268-K · 7.01MCR improvement after first year 8; MCR improvement by year four 20; Clover Care Services enrollment growth 90open

Figures in the filing · each found in the filing text

MCR improvement after first year · Clover Assistant cohort · Q1-20268.0%
MCR improvement by year four · Clover Assistant cohort · Q1-202620.0%
Clover Care Services enrollment growth · Clover Care Services · Q1-202690.0%

Guidance

No formal guidance change; management reaffirms full-year focus and will reassess after Q2. Positive tone on cohort margin expansion and enrollment growth.

Risks flagged

Seasonality in medical costs could lead to earnings variability within the year, though managed on full-year basis.

“gross profit is typically stronger in the first half of the year, with costs building as the year progresses” · word for word

IRA-related changes to Part D seasonality may introduce additional uncertainty.

“IRA-related changes to Part D seasonality that began in 2025” · word for word
Read the original on SEC EDGAR ↗
8 May 202610-QTotal revenues $749M (+62% y/y); Net income $27M; Adjusted EBITDA $40M (+56% y/y)open

Figures in the filing · each found in the filing text

Total revenues · Q1-2026$749M+62% y/y
Net income · Q1-2026$27M
Adjusted EBITDA · Q1-2026$40M+56% y/y
Average Medicare Advantage membership · Q1-2026154,607+52% y/y
Premiums earned, net · Q1-2026$744M+63% y/y
Insurance Benefits Expense Ratio · Q1-202686.5%
Operating cash flow · Q1-2026$108M
Free cash flow · Q1-2026$103M
Adjusted SG&A · Q1-2026$119M+44% y/y
Adjusted Net income · Q1-2026$40M+57% y/y

Risks flagged

Medical Cost Ratio Pressure

“Insurance Benefits Expense Ratio 86.5 % vs 86.1 %, an increase of 40 basis points” · word for word

Regulatory Dependency

“We earn premiums through our plans offered under contracts with CMS.” · word for word

Star Rating Risk

“we are currently being paid on 4.0 stars in the current year as compared to 3.5 stars in the prior period” · word for word
Read the original on SEC EDGAR ↗
6 May 20268-K · 2.02Total revenues $749M (+62% y/y); Consolidated Gross profit $160M (+46% y/y); Net income (loss) $27M; Guidance: FY2026 revenue $2.81B-$2.92B (midpoint $2.865B, +49% YoY); Gross profit $470M-$510M; Adj EBITDA $50M-$70M; GAAP Net Income $0M-$2earningsopen

Figures in the filing · each found in the filing text

Total revenues · Consolidated · Q1-2026$749M+62% y/y
Consolidated Gross profit · Consolidated · Q1-2026$160M+47% y/y
Net income (loss) · Consolidated · Q1-2026$27M
Adjusted EBITDA · Consolidated · Q1-2026$40M+56% y/y
Average Medicare Advantage membership · Insurance · Q1-2026154,607+52% y/y
Insurance revenue · Insurance · Q1-2026$744M+63% y/y
Insurance BER · Insurance · Q1-202686.5%
Total cash, cash equivalents, and investments · Consolidated · Q1-2026$418M+7% y/y
Adjusted Net income · Consolidated · Q1-2026$40M+57% y/y
Adjusted SG&A · Consolidated · Q1-2026$119M+44% y/y

Guidance

FY2026 revenue $2.81B-$2.92B (midpoint $2.865B, +49% YoY); Gross profit $470M-$510M; Adj EBITDA $50M-$70M; GAAP Net Income $0M-$20M

Management raised full-year guidance across all metrics, expecting first full year of GAAP net income profitability.

Risks flagged

Insurance BER increased slightly to 86.5% from 86.1%, indicating potential medical cost pressure.

“Insurance BER 86.5% vs 86.1% prior year, up 40 bps”
Read the original on SEC EDGAR ↗
28 Apr 2026DEF 14AAnnual proxy statement filed; no material event.open

Figures in the filing · each found in the filing text

Net Income (Loss) · FY2025$-86M
Star Rating · FY2025$3.50
Total Shareholder Return (TSR) · FY2025$14.67

Risks flagged

Stars rating dependency

“in light of only achieving a 3.5 Stars rating, which triggered a cutback that reduced the 2025 overall bonus achievement level by 50%, determined that no bonuses would be paid to the NEOs in respect of the 2025 annual bonus period.” · word for word

Related party concentration

“Expenses and fees incurred related to these contracts, recorded in net medical claims incurred, were $4.4 million for the year ended December 31, 2025. ... Expenses and fees incurred related to this agreement was $1.5 million for the year ended December 31, 2025. ... Expenses and fees incurred related to this agreement was $8.3 million for the year ended Dec” · word for word
Read the original on SEC EDGAR ↗
1 Apr 20268-K · 5.02, 8.01Reported the departure of a director or principal officer (CEO/CFO change); disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open

Risks flagged

Leadership change could introduce uncertainty in strategy execution.

“Departure of a director or principal officer.”
Read the original on SEC EDGAR ↗
6 Mar 20268-K · 7.01Clover Health published supplemental Q&A responses to shareholder questions from Q4 2025 earnings. No new material financial or operational information disclosed.SEC ↗
27 Feb 202610-KStar Rating - PPO 3.5; Star Rating - HMO 4open

Figures in the filing · each found in the filing text

Star Rating - PPO · PPO · 20263.5
Star Rating - HMO · HMO · 20264

Risks flagged

Medicare Advantage funding risk

“We derive substantially all of our Total revenues from Medicare Advantage premiums and expect to continue to derive a substantial portion of our Total revenues in the future from Medicare Advantage premiums.” · word for word

DOJ investigation / FCA risk

“As previously disclosed, we have received an inquiry from the U.S. Department of Justice ("DOJ")” · word for word

FDA regulation of Clover Assistant

“If the FDA determines that any of our current or future analytics applications, including Clover Assistant, are regulated as medical devices, we would become subject to various requirements under the FDCA and the FDA's implementing regulations.” · word for word

Star Rating dependency

“Failure to maintain satisfactory quality and performance measures may negatively affect our premium rates, subject us to penalties, limit or reduce our number of members.” · word for word

Change Healthcare breach impact

“In 2024, one of our vendors, UnitedHealth Group's Change Healthcare, experienced a ransomware attack, which compromised certain of our members' personal information (including protected health information).” · word for word
Read the original on SEC EDGAR ↗
26 Feb 20268-K · 2.02Consolidated Gross Profit $356M (-2% y/y); Net Loss from Continuing Operations $-86M (+85% y/y); Adjusted EBITDA $22M (-69% y/y); Guidance: Revenue guidance $2.81B-$2.92B (+49% YoY midpoint); GAAP Net Income $0-$20M (first-ever profitabilitearningsopen

Figures in the filing · each found in the filing text

Consolidated Gross Profit · FY2025$356M-2% y/y
Net Loss from Continuing Operations · FY2025$-86M+85% y/y
Adjusted EBITDA · FY2025$22M-69% y/y
Average Medicare Advantage Membership · Insurance · FY2025107,084+33% y/y
Insurance Revenue · Insurance · FY2025$1.89B+41% y/y
Insurance BER · Insurance · FY202590.9%
Total Cash, Cash Equivalents, and Investments · FY2025$320M-27% y/y

Guidance

Revenue guidance $2.81B-$2.92B (+49% YoY midpoint); GAAP Net Income $0-$20M (first-ever profitability)

Strong guidance for 2026 with significant revenue growth, first GAAP net income profitability, and improving cohort economics.

Risks flagged

Insurance BER increased to 90.9% from 81.2% due to higher medical claims incurred.

“Insurance BER 90.9%, up 970 bps year-over-year. Normalized Insurance BER 91.5%, up 730 bps.”

Cash and investments decreased 26.9% YoY, indicating cash burn.

“Total cash, cash equivalents, and investments $319.9 million, down 26.9% year-over-year.”
Read the original on SEC EDGAR ↗
14 Jan 20268-K · 7.01Medicare Advantage membership growth (AEP) 53; HEDIS quality score 4.72; Guidance: FY26 GAAP Net Income profitability; sustained Adjusted EBITDA profitabilityopen

Figures in the filing · each found in the filing text

Medicare Advantage membership growth (AEP) · Q1-202653.0%
HEDIS quality score · PPO · FY2026$4.72

Guidance

FY26 GAAP Net Income profitability; sustained Adjusted EBITDA profitability

Company raises guidance by targeting GAAP Net Income profitability in FY26, supported by strong AEP growth and clinical quality leadership.

Risks flagged

Medical cost trend and cohort economics could pressure margins if utilization rises unexpectedly.

“Strong medical cost trend & cohort economics, gaining SG&A leverage” · word for word
Read the original on SEC EDGAR ↗
10 Dec 20258-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportopen

Risks flagged

No specific financial data; boilerplate risk factors.

Read the original on SEC EDGAR ↗
12 Nov 20258-K · 7.01Underlying incurred Part C medical cost trend (excluding pharmacy) 4; Guidance: Expect notable improvement in both new and returning cohorts contribution profit in 2026open

Figures in the filing · each found in the filing text

Underlying incurred Part C medical cost trend (excluding pharmacy) · Q3-20254.0%

Guidance

Expect notable improvement in both new and returning cohorts contribution profit in 2026

Management confident in 2026 profitability expansion due to star rating, rate update, and member cohort maturation.

Risks flagged

Medical cost pressures from new member cohorts could persist if retention or care management does not improve.

“We saw elevated utilization across all cohorts, consistent with broader industry trends, with pressures more pronounced within new member cohorts.” · word for word
Read the original on SEC EDGAR ↗
7 Nov 202510-QClover Health reported Q3 2025 results with strong membership growth but significantly higher medical cost ratio and lower adjusted EBITDA, alongside a CMS star rating downgrade for its PPO plans.earningsopen

Figures in the filing · each found in the filing text

Insurance members at period end · Insurance · Q3-2025109,226+35% y/y
Premiums earned, net · Insurance · Q3-2025$479M+49% y/y
Benefits expense ratio, gross · Insurance · Q3-202593.5%
Normalized benefits expense ratio, gross · Insurance · Q3-202592.4%
Adjusted EBITDA · Q3-2025$2M-89% y/y
Adjusted Net income from continuing operations · Q3-2025$2M-91% y/y
Cash, cash equivalents, and investments · 2025-09-30$396M

Risks flagged

Star Rating Downgrade Risk

“CMS has decreased the Star rating of its PPO Medicare Advantage plans to 3.5 Stars for 2026, which will affect payment year 2027.” · word for word

Medical Cost Ratio Deterioration

“Benefits expense ratio, gross 93.5 % ... 82.8 %” · word for word
Read the original on SEC EDGAR ↗
4 Nov 20258-K · 7.01Total revenues $497M (+50% y/y); Insurance revenue $479M (+48% y/y); Net loss from continuing operations $-24M; Guidance: Adjusted EBITDA guidance cut from $50-70M to $15-30M; Insurance BER raised to 90-91% from 88.5-89.5%.open

Figures in the filing · each found in the filing text

Total revenues · Q3-2025$497M+50% y/y
Insurance revenue · Insurance · Q3-2025$479M+49% y/y
Net loss from continuing operations · Q3-2025$-24M
Adjusted EBITDA · Q3-2025$2M-89% y/y
Average Medicare Advantage membership · Medicare Advantage · Q3-2025108,231+34% y/y
Insurance BER · Insurance · Q3-202593.5%
Adjusted SG&A · Q3-2025$71M+15% y/y
Total cash, cash equivalents, and investments · Q3-2025$396M-26% y/y

Guidance

Adjusted EBITDA guidance cut from $50-70M to $15-30M; Insurance BER raised to 90-91% from 88.5-89.5%.

Revenue and membership growth strong, but margin pressure from new member mix and utilization leads to significant guidance cut for profitability. FY2026 outlook positive with star rating and rate tailwinds.

Risks flagged

Guidance cut reflects higher-than-expected new member mix and elevated utilization pressuring margins.

“Adjusted EBITDA guidance cut from $50-70M to $15-30M; Insurance BER guidance raised to 90-91%.”

Cash burn; cash reserves down 25.5% YoY to $395.9M.

“Total cash, cash equivalents, and investments $395.9M vs $531.4M.”

Dependence on CMS rate updates and star ratings for profitability improvement in 2026.

“FY2026 outlook relies on 4.0 Star payment year and favorable CMS rate update.”
Read the original on SEC EDGAR ↗
31 Oct 20258-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen

Risks flagged

Board vacancy may reduce governance oversight temporarily.

“Board will continue to operate with two vacant seats” · word for word
Read the original on SEC EDGAR ↗

Clover Health Investments, Corp. — questions

What did Clover Health Investments, Corp. file recently?
23 SEC filings in the last 12 months. Latest: 8-K on 2026-10-09 — CMS awarded Clover's PPO MA plans 5 Stars and HMO plan 4.5 Stars for 2027, enabling year-round enrollment and higher payments; core HEDIS score remains 4.82/5, ranking #1 among non-SNP PPO plans.

Every figure on this page comes from Clover Health Investments, Corp.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.